Exploring the relation between human papilloma virus and larynx cancer

Acta Oto-Laryngologica

Volumn 127, Issue 9, 2007, Pages 900-906

  Torrente, Mariela C ^a,c   Ojeda, Jose M ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c NONE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; PROTEIN E6; PROTEIN E7; PROTEIN P53; VIRUS DNA; WART VIRUS VACCINE;

CONDYLOMA; DISEASE ASSOCIATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; LARYNX CANCER; NONHUMAN; ONCOGENE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UTERINE CERVIX CANCER; WART VIRUS;

CELL TRANSFORMATION, NEOPLASTIC; GENOTYPE; HUMANS; LARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 34548331830     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480601110238     Document Type: Review

References (46)

1. Ullman EV. On the aetiology of the laryngeal papilloma. Acta Otolaryngol (Stockh) 1923;5:317-34.
2. Snijders PJF, Steerbergen DM, Heideman DAM, Meijer CLJM. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-64.
3. Bromberg-White JL, Meyers C. Comparison of the basal and glucocorticoid-inducible activities of the upstream regulatory regions of HPV18 and HPV31 in multiple epithelial cell lines. Virology 2003;306:197-202.
4. Bernard HU, Calleja-Macias IE, Dunn ST. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer 2006;118:1071-6.
5. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27.
6. Baseman JG, Koutsy LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32S:S16-S24.
7. Muñoz N, Bosch X, de Sanjose S, Herrero R, Castellsague X, Shah K, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
8. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57.
9. Cuschieri KS, Cubie HA, Whitley MW, Scagar AL, Arends MJ, Moore C, et al. Multiple high-risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004;57:68-72.
10. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
11. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
12. Pagliusi SR, Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-78.
13. Nuñez DA, Astley SM, Lewis FA, Wells M. Human papilloma viruses: a study of their prevalence in the normal larynx. J Laryngol Otol 1994;108:319-20.
14. Gorgoulis VG, Zacharatos P, Kotsinas A, Kyroudi A, Rassidakis A, Ikonomopoulos J, et al. Human Papilloma Virus (HPV) is possibly involved in laryngeal but not in lung carcinogenesis. Hum Pathol 1999;30:274-83.
15. Rihkanen H, Peltomaa J, Syrjanen S. Prevalence of human papillomavirus (HPV) DNA in vocal cords without laryngeal papillomas. Acta Otolaryngol (Stockh) 1994;114:348-51.
16. Smith EM, Summersgill KF, Allen J, Hoffman HT, McCulloch T, Turek LP, et al. Human papillomavirus and risk of laryngeal cancer. Ann Otol Rhinol Laryngol 2000;109:1069-86.
17. Azzimonti B, Hertel L, Aluffi P, Pia F, Monga G, Zocchi M, et al. Demonstration of multiple HPV types in laryngeal premalignant lesions using polymerase chain reaction and immunohistochemistry. J Med Virol 1999;59:110-6.
18. Egawa K. Do human papillomaviruses target epidermal stem cells? Dermatology 2003;207:251-4.
19. Schmitt A, Rochat A, Zeltner R, Borenstein L, Barrandon Y, Wettstein FO, et al. The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. J Virol 1996;70:1912-22.
20. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J Virol 2001;75:1565-70.
21. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 1999;274:5810-22.
22. Culp TD, Christensen ND. Kinetics of in vitro adsorption and entry of papillomavirus virions. Virology 2004;319:152-61.
23. Day PM, Lowy DR, Schiller JT. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003;307:1-11.
24. Selinka HC, Giroglou T, Sapp M. Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. Virology 2002;299:279-87.
25. Storey A, Thomas M, Kalita A, Harwood C, Gardio D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus associated cancer. Nature 1998;393:229-34.
26. Jee SH, Won SY, Yun JE, Lee JE, Park JS, Ji SS. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet 2004;85:301-8.
27. Sanches S, Jocelan P, Sobrinho JS, Mann-Prado JC, Pizzo PM, Nobre de Freitas SE, et al. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. Cancer Genet Cytogenet 2004;150:44-9.
28. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002;89:229-40.
29. Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope 2001;111:57-69.
30. Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus-11- associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 2001;4:68-72.
31. Herrero R. Human papillomavirus and cancer of the upper aerodigestive tract. J Natl Cancer Inst Monogr 2003;31:47-51.
32. Almadori G, Cadoni G, Cattani P, Galli J, Bussu F, Ferrandina G, et al. Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma. Clin Cancer Res 2001;7:3988-93.
33. Atula S, Grenman R, Kujari H, Syrjänen S. Detection of human papillomavirus (HPV) in laryngeal carcinoma cell lines provides evidence for a heterogeneic cell population. Eur J Cancer 1999;35:825-32.
34. Venuti A, Manni V, Morello R, De Marco F, Marzetti F, Marcante ML. Physical state and expression of human papillomavirus in laryngeal carcinoma and surrounding normal mucosa. J Med Virol 2000;60:396-402.
35. Brandwein MS, Biller H, Nuovo GJ. Analysis of prevalence of human papilloma virus in laryngeal carcinomas. Ann Otol Rhinol Laryngol 1993;102:309-13.
36. Lie ES, Karlsen F, Holm R. Presence of human papilloma virus in squamous cell laryngeal carcinomas. A study of thirty-nine cases using polymerase chain reaction and in situ hybridization. Acta Otolaryngol (Stockh) 1996;116:900-5.
37. Pérez-Ayala M, Ruiz-Cabello F, Esteban F, Concha A, Redendo M, Oliva MR, et al. Presence of HPV 16 sequences in laryngeal carcinomas. Int J Cancer 1990;46:8-11.
38. Torrente M, Abud S, Abud M, Ojeda JM. Molecular detection and genotyping of human papillomavirus in laryngeal carcinoma specimens. Acta Otolaryngol (Stockh) 2005;125:888-93.
39. Fouret P, Monceaux G, Temam S, Lacourreye L, Lacau St Guily J. Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg 1997;123:513-6.
40. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
41. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75.
42. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992;89:12180-4.
43. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
44. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364:1757-65.
45. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247-55.
46. Roden R, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004;35:971-82.